Get the Stockscreener App
27.50
0.18%
-0.05
After Hours:
28.05
0.55
+2.00%
Spyglass Pharma Inc stock is traded at $27.50, with a volume of 64,308.
It is down -0.18% in the last 24 hours and up +0.00% over the past month.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
See More
Previous Close:
$27.55
Open:
$27.96
24h Volume:
64,308
Relative Volume:
10.20
Market Cap:
$916.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$27.15
$28.48
1-Week Range:
$24.71
$28.93
52-Week Range:
$24.71
$28.93
Spyglass Pharma Inc Stock (SGP) Company Profile
Compare SGP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
27.50 | 917.89M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Spyglass Pharma Inc Stock (SGP) Latest News
New Enterprise Associates 17, L.P. Increases Stake in SpyGlass P - GuruFocus
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering - Legal Desire Media and Insights
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma closes $172.5 million IPO on NASDAQ - Investing.com
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - ChartMill
Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO - TipRanks
SpyGlass Pharma Raises $150 Million in Initial Public Offering - VisionMonday.com
SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One - Smartkarma
SpyGlass Pharma, Developer of Long-Acting Ocular Drug-Delivery Implants for Glaucoma and Other Chronic Eye Conditions, Files for Nasdaq Global Select Market IPO - TradingView
Eye Care Firm SpyGlass Pharma Soars 50% After $150 Million IPO - Bloomberg.com
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts - Intellectia AI
Spyglass Pharma shares surge 50% in Nasdaq debut By Investing.com - Investing.com Canada
Eye care firm SpyGlass Pharma soars 50% after $150 million IPO - MSN
SpyGlass Pharma raises $150 million in IPO priced at $16 per share - Investing.com Australia
SpyGlass Pharma Rings the Opening Bell - Nasdaq
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments - Intellectia AI
SpyGlass Pharma raises $150 million in IPO priced at $16 per share By Investing.com - Investing.com South Africa
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
SGP IPO NewsChronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint - renaissancecapital.com
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO - Wilson Sonsini
SpyGlass Pharma prices IPO at $16 per share, raising $150 million - Investing.com Nigeria
SpyGlass Pharma prices IPO at $16 per share, raising $150 million By Investing.com - Investing.com South Africa
SpyGlass Pharma announces pricing of IPO at $16.00 per share - marketscreener.com
Spyglass Pharma Announces Pricing Of IPO At $16.00 Per Share - TradingView
Late-stage biopharma SpyGlass Pharma to debut on Nasdaq after $150M IPO - Stock Titan
SpyGlass Pharma Announces Pricing of Initial Public Offering - Yahoo Finance
IPO Rating: Spyglass Pharma Inc. - Smartkarma
SpyGlass Pharma Sets Terms for IPO as Ophthalmology-Focused Biotech Advances Sustained-Release Platform - Smartkarma
SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week - Smartkarma
First Look | SpyGlass Pharma (Pending:SGP) - Seeking Alpha
SpyGlass Pharma, Inc. (SGP): Peeking at the IPO Prospectus Of Company Transforming Glaucoma Care - Smartkarma
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System - Yahoo Finance
SpyGlass Pharma Files $100M IPO - Orange County Business Journal
SpyGlass Pharma files for proposed IPO By Investing.com - Investing.com Canada
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer - GlobeNewswire
SpyGlass Pharma Announces Positive 36-Month First-in-Human - GlobeNewswire
Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months - Ophthalmology Times
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial - GlobeNewswire
SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors - Yahoo Finance
SpyGlass Pharma Raises $75M Series D Round - Orange County Business Journal
SpyGlass Pharma secures $75m for ophthalmic drug delivery platform - Pharmaceutical Technology
SpyGlass Pharma raises $75M for drug delivery platform - Drug Delivery Business
SpyGlass Pharma Presents 18-Month Data Demonstrating - GlobeNewswire
SpyGlass Pharma Completes Enrollment in Phase I/II Study of - GlobeNewswire
SpyGlass Posts Positive Early Data in IOL Clinical Trial - Orange County Business Journal
SpyGlass Pharma unveils 1-year data of drug delivery platform implanted during routine cataract surgery in patients diagnosed with glaucoma - Ophthalmology Times
SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases - PRWeb
SpyGlass Pharma releases 6-month data from first-in-human trial for glaucoma - Eyes On Eyecare
Spyglass Pharma Inc Stock (SGP) Financials Data
There is no financial data for Spyglass Pharma Inc (SGP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):